Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
暂无分享，去创建一个
V. Gushchin | A. Gintsburg | D. Logunov | B. Naroditsky | O. Popova | S. Borisevich | F. Izhaeva | S. Zyryanov | D. V. Voronina | A. Tukhvatulin | E. Smolyarchuk | D. Shcheblyakov | O. Zubkova | I. Esmagambetov | I. Dolzhikova | A. Dzharullaeva | A. Erokhova | A. Semikhin | E. Tokarskaya | N. Nikitenko | I. Favorskaya | D. I. Zrelkin | A. Kovyrshina | D. Egorova | M. Shmarov | D. Grousova | A. G. Botikov | Y. Simakova | T. Ozharovskaya | D. Shcherbinin | N. Lubenets | Daria V. Voronina